- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 274
Oracle catches DataFox
Alphabet and Slack have exited business intelligence software provider DataFox in an acquisition of undisclosed size by Oracle.
Oct 25, 2018Tuanche starts engine on $150m IPO
Bertelsmann Asia Investments owns almost 10% of the Chinese automotive marketplace, which has filed to raise up to $150m in a US offering.
Oct 25, 2018Dome9 reaches Check Point in $175m acquisition
Cloud security software provider Dome9 has been acquired by Check Point for $175m plus stock and options, following $29m in funding from investors including SoftBank.
Oct 25, 2018Innovent enters public markets with $421m IPO
Legend Holdings, Eli Lilly, Ping An, China Life and Taikang-backed Innovent Biologics priced its shares near the top of the range of to raise $421m.
Oct 24, 2018Cloudflare looks to deliver 2019 IPO
Cloudflare, which has raised more than $180m from investors including Microsoft, Baidu, Qualcomm Ventures and GV, could command a $3.5bn valuation in the offering.
Oct 24, 2018Ant Financial backs StoneCo on way to $1.1bn IPO
Payment technology provider StoneCo will raise about $1.1bn if it floats at the top of its range, while Ant Financial is investing $100m through a private placement.
Oct 24, 2018Chefs Plate reaches HelloFresh's table
Tengelmann-backed Emil Capital will exit meal kit service Chefs Plate in an acquisition by HelloFresh sized in the mid-eight figures.
Oct 24, 2018ZoneFox enters Fortinet perimeter
Fortinet has acquired Edinburgh Napier spinout ZoneFox for an undisclosed sum and will integrate the company’s machine learning technology into its own cybersecurity offering.
Oct 24, 2018Tongcheng-eLong journeys towards $1bn IPO
The online travel agency is reportedly seeking $1bn from an initial public offering in Hong Kong that would provide exits to Tencent, Ctrip and Dalian Wanda.
Oct 23, 2018PhaseBio finds $46m in initial public offering
Orphan disease drug developer PhaseBio Pharmaceuticals, which is commercialising research from Duke University, cut the price of its shares sharply pre-offering.
Oct 23, 2018About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


